

Mar 5, 2019

CURRICULUM VITAE

Personal Informations:

Yosuke MINAMI, MD, PhD

Birth Date: July 5, 1970
Birth Place: Wakayama, Japan
Citizenship: Japan
E-mail: yominami@east.ncc.go.jp

Education:

1990- 1996 Bachelor of M.D., Nagoya University School of Medicine, Japan
1999- 2003 Ph.D., Nagoya University Graduate School of Medicine, Japan

Professional Training and Employment:

1996-1998 Resident of Internal Medicine, Komaki Municipal Hospital, Japan
1998-1999 Clinical Staff, Department of Hematology, Komaki Municipal Hospital
1999- 2003Mar Ph.D. course, Department of Hematology and Oncology, Nagoya University Graduate School of Medicine and Clinical Staff, Nagoya University Hospital, Japan
2003Apr- Sep Research Fellow, Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, and Clinical Staff, Department of Hematology, Chukyo Hospital, Japan
2003Oct- 2008 Research Associate, Division of Hematology-Oncology, Department of Medicine and Moores Cancer Center, University of California San Diego (UCSD) School of Medicine, USA
2008-2013 Lecturer, Department of Hematology and Oncology, Nagoya University Graduate School of Medicine and Clinical Staff, Nagoya University Hospital, Japan
2013-2017Mar Associate Professor, Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Japan
2017Apr- Chief, Department of Hematology, National Cancer Center Hospital East, Japan

Memberships (selected):

PMDA (Pharmaceuticals and Medical Device Agency): medical expert adviser
JALSG (Japan Adult Leukemia Study Group): CML 212 committee (Vice-PI), geriatric AML committee member, STIM213 committee member

The Japanese Society of Hematology (with Board Certification / Councilor)
The Japanese Society of Clinical Oncology (Councilor)
The Japanese Cancer Association (Councilor)
The Japanese Association for Molecular Target Therapy of Cancer (Councilor)
The Japanese Society of Internal Medicine (with Board Certification)
The American Society of Hematology (the 57th ASH annual meeting, program committee member: CML therapy)

The American Society of Clinical Oncology

Honors (Selected):

2001, Plenary Speech, The 63rd Japanese Society of Hematology Meeting
2007, Scholarship & Plenary Speech, Keystone Symposia (Stem Cells and Cancer)
2009, Scholarship & Plenary Speech, Gordon Research Conferences (Stem Cells and Cancer)
2011, Select oral presentation, The *53rd ASH meeting*
2015, Meeting moderator (CML oral session), The *57th ASH meeting*

Research themes:

Translational research of molecular-targeting therapy for leukemia

Publications (selected):

- 1) The attenuation of suppression of motility by triazolam in the conditioned fear stress task is exacerbated by ethanol in mice
K Kitaichi, Y Minami, M Amano, K Yamada, T Hasegawa, and T Nabeshima
Life Science, 57 (8): 743-753, 1995
- 2) Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis
K Kitamura*, Y Minami*, K Yamamoto, Y Akao, H Kiyoi, H Saito, and T Naoe (**These authors contributed equally*)
Leukemia, 14 (10): 1743-1750, 2000
- 3) FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy
T Naoe, H Kiyoi, Y Yamamoto, Y Minami, K Yamamoto, R Ueda, and H Saito
Cancer Chemotherapy and Pharmacology, 48 (Suppl 1): 27-30, 2001
- 4) Selective apoptosis of FLT3/ITD-transformed leukemia cells by Hsp90 inhibitors
Y Minami, H Kiyoi, Y Yamamoto, K Yamamoto, R Ueda, H Saito, and T Naoe
Leukemia, 16 (8): 1535-1540, 2002
- 5) Different anti-apoptotic pathways between wild and mutated FLT3: insights into therapeutic targets in leukemia
Y Minami, K Yamamoto, H Kiyoi, R Ueda, H Saito, and T Naoe
Blood, 102 (8): 2969-2975, 2003
- 6) Abl and Cell Death: *Abl Family Kinases in Development and Disease*, Edited by AJ Koleske
JYJ Wang, Y Minami, and J Zhu
Landes Bioscience: 26-47, 2006
- 7) BCR-ABL-transformed GMP as myeloid leukemic stem cells
Y Minami, SA Stuart, T Ikawa, Y Jiang, A Banno, IC Hunton, DJ Young, T Naoe, C Murre, CHM Jamieson, and JYJ Wang
Proc Natl Acad Sci USA, 105 (46): 17967-17972, 2008
- 8) Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myeloid leukemia after imatinib therapy
A Abe, Y Minami, F Hayakawa, K Kitamura, Y Nomura, M Murata, A Katsumi, H Kiyoi, CHM Jamieson, JYJ Wang, and T Naoe
Int J Hematol, 88 (5): 171-175, 2008
- 9) KW-2449, a novel multi-kinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Y Shiotsu, H Kiyoi, Y Ishikawa, R Tanizaki, M Shimizu, H Umehara, K Ishii, Y Mori, K Ozeki, Y Minami, A Abe, H Maeda, T Akiyama, Y Kanda, Y Sato, S Akinaga, and T Naoe
Blood, 114 (8): 1607-1617, 2009
- 10) The CML stem cell: evolution of the progenitor
SA Stuart, Y Minami, and JYJ Wang
Cell Cycle, 8 (9): 1338-1343, 2009
- 11) BCR-ABL-independent and RAS/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4

M Suzuki, A Abe, S Imagama, Y Nomura, R Tanizaki, Y Minami, F Hayakawa, Y Ito, A Katsumi, K Yamamoto, N Emi, H Kiyoi, and T Naoe
Eur J Haematol, 84 (3): 229-238, 2010

12) Treatment with everolimus overcomes resistance to imatinib in Ph-leukemia quiescent or T315I-mutated cells
Y Minami (Corresponding Author), M Minami, Y Kuwatsuka, R Tanizaki, A Abe, H Kiyoi, and T Naoe
Annals of Oncology, 21 (Suppl 9): 34, 2010

13) Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and reestablishes transformed Philadelphia chromosome-positive leukemia in NOG mice
R Tanizaki*, Y Nomura*, Y Miyata, Y Minami, A Abe, A Hanamura, M Sawa, M Murata, H Kiyoi, T Matsushita, and T Naoe (**These authors contributed equally*)
Cancer Sci, 101 (3): 631-638, 2010

14) Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib-treatment
Y Minami* (*Corresponding Author*), T Kajiguchi*, A Abe, T Ohno, H Kiyoi, and T Naoe (**These authors contributed equally*)
Int J Hematol, 92 (4): 664-666, 2010

15) A novel insertion mutation of K294RGG within *BCR-ABL* kinase domain confers imatinib-resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis
K Sakai, Y Ishikawa, Y Mori, M Kobayashi, C Iriyama, Y Ozawa, T Suzuki, Y Minami, K Ishikawa, N Kaneda, T Naoe, and H Kiyoi
Int J Hematol, 93 (2): 237-242, 2011

16) PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML
S Kurahashi, F Hayakawa, Y Miyata, T Yasuda, Y Minami, A Abe, S Tsuzuki, and T Naoe
Oncogene, 30 (15): 1822-1830, 2011

17) Treatment with mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
Y Kuwatsuka, M Minami, Y Minami (Corresponding Author), K Sugimoto, F Hayakawa, Y Miyata, A Abe, DJ Goff, H Kiyoi, and T Naoe
Blood Cancer J, 1 (5): e17, 2011

18) T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype; 3 case reports
K Watanabe, Y Minami (Corresponding Author), Y Ozawa, K Miyamura, and T Naoe
Anticancer Res, 32 (5): 1779-1783, 2012

19) Biomarker assay for residual chronic myeloid leukemia stem/progenitor cells during treatment with ABL-tyrosine kinase inhibitors
Y Minami (Corresponding Author), and T Naoe
J Mol Biomark Diagn, S8-001, 2012

20) B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation: a mechanism of antigen-triggering plasma cell differentiation
T Yasuda, F Hayakawa, S Kurahashi, K Sugimoto, Y Minami, A Tomita, and T Naoe
J Immunol, 188 (12): 6127-6134, 2012

21) CML cells expressing the TEL/MDS1/EVI1 fusion protein are resistant to imatinib-induced apoptosis through inhibition of BAD but can be resensitized to die by the administration of ABT-737

K Shimada, A Tomita, Y Minami, R Tanizaki, CK Hind, A Abe, H Kiyoi, MS Cragg, and T Naoe

Exp Hematol, 40 (9): 724-737, 2012

22) Retention of CD34⁺CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors

Y Minami (Corresponding Author), A Abe, M Minami, K Kitamura, J Hiraga, S Mizuno, K Yamamoto, M Sawa, Y Inagaki, K Miyamura, and T Naoe

Leukemia, 26 (9): 2142-2143, 2012

23) Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia

S Katagiri, T Tauchi, S Okabe, Y Minami, S Kimura, T Maekawa, T Naoe, and K Ohyashiki

Clin Cancer Res, 19 (6): 1422-1432, 2013

24) Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice

K Yamamoto, S Tsuzuki, Y Minami, Y Yamamoto, A Abe, K Ohshima, M Seto, and T Naoe

PLoS One, 8 (9): e74864, 2013

25) Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia

T Shibata, Y Minami, A Mitsuma, S Morita, M Inoue, T Shimokata, M Sugishita, T Oguri, T Naoe, and Y Ando

Int J Clin Oncol, 19 (2): 391-396, 2014

26) Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia

Y Nishida, N Mizutani, M Inoue, Y Omori, K Tamiya-Koizumi, A Takagi, T Kojima, M Suzuki, M Nozawa, Y Minami, K Ohnishi, T Naoe, and T Murate

Biochim Biophys Acta, 1839 (4): 265-274, 2014

27) Properties of chronic myeloid leukemia stem cells: strategy based on the kinetics during treatment with ABL-tyrosine kinase inhibitors

Y Minami (Corresponding Author)

J Hematol Transfus, 2 (3): 1025-1029, 2014

28) Treatment with Hedgehog inhibitor, PF-913, attenuates leukemia-initiation potential in acute myeloid leukemia cells

Y Minami (Corresponding Author), N Fukushima, S Kakiuchi, H Minami, and T Naoe

Annals of Oncology, 25 (Suppl 5), 2014

29) Heme-related molecules induce rapid production of neutrophil extracellular traps

M Kono, K Saigo, Y Takagi, T Takahashi, S Kawachi, A Wada, M Hashimoto, Y Minami, S Imoto, M Takenokuchi, T Morikawa, and K Funakoshi

Transfusion, 54 (11): 2811-2819, 2014

30) Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoforms expression profile mediated by bcr-abl in chronic myeloid leukemia

H Shinohara, K Taniguchi, M Kumazaki, N Yamada, Y Ito, Y Otsuki, B Uno, F Hayakawa,

Y Minami, and T Naoe
Cancer Letter, 360 (1): 28-38, 2015

31) Rhabdomyolysis caused by *Candida parapsilosis* in a patient with acute myeloid leukemia after bone marrow transplantation
S Kakiuchi, K Yakushijin, K Yamamoto, H Tomioka, Y Inui, A Okamura, S Kawamoto, Y Minami, T Murayama, M Ito, H Matsuoka, and H Minami
Intern Med, 54 (16): 2057-2060, 2015

32) Cancer stem cell and tumor environment
Y Minami (Corresponding Author)
Oncology, 89 (Suppl 1): 22-24, 2015

33) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained complete molecular response for at least 1 year: the prospective, multicentre Dasatinib-Discontinuation (DADI) Trial
J Imagawa, H Tanaka, M Okada, H Nakamae, M Hino, K Murai, Y Ishida, T Kumagai, S Sato, K Ohashi, H Sakamaki, H Wakita, N Uoshima, Y Nakagawa, Y Minami, M Ogasawara, T Takeoka, H Akasaka, T Utsumi, N Uike, T Sato, H Sakai, K Usuki, S Morita, J Sakamoto, and S Kimura, on behalf of the DADI Trial Group, JAPAN
Lancet Haematology, 2 (12): e528-535, 2015

34) Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL harboring leukemic cells
H Shinohara, M Kumazaki, Y Minami, N Sugito, Y Kuranaga, K Taniguchi, N Yamada, T Naoe, and Y Akao
Cancer Letter, 371 (1): 1-11, 2016

35) Wnt signaling is associated with cell survival in the interaction between acute myeloid leukemia cells and stromal cells
Y Niwa, Y Minami (Corresponding Author), A Abe, F Hayakawa, K Yamada, and T Naoe
Leuk Lymphoma, 57 (9): 2192-2194, 2016

36) A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy
Y Sanada, K Yakushijin, T Nomura, N Chayahara, M Toyoda, Y Minami, K Kiyota, T Mukohara, S Kawamoto, M Ito, H Matsuoka, and H Minami
Jpn J Clin Oncol, 46 (5): 448-452, 2016

37) Iron chelating agent, Deferasirox, inhibits neutron activation and extracellular trap (NET) formation
M Kono, K Saigo, S Yamamoto, K Shirai, S Iwamoto, T Uematsu, T Takahashi, S Imoto, M Hashimoto, Y Minami, A Wada, M Takenouchi, and S Kawano
Clin Exp Pharmacol Physiol, 43: 915-920, 2016

38) Small-molecule Hedgehog inhibitor attenuates leukemia-initiation potential in acute myeloid leukemia
N Fukushima, Y Minami (Corresponding Author), S Kakiuchi, Y Kuwatsuka, F Hayakawa, C Jamieson, H Kiyoi, and T Naoe
Cancer Sci, 107 (10): 1422-1429, 2016

39) Sea-blue histiocytes in acute myeloid leukemia with trisomy 9
K Yamamoto, Y Minami, K Yakushijin, S Kawamoto, K Kurata, T Kikuma, H Matsuoka, and H Minami

Int J Hematol, 104 (5): 531-533, 2016

40) A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen
Y Miyata, K Yakushijin, Y Inui, Y Imamura, H Goto, Y Mizutani, K Kurata, S Kakiuchi, Y Sanada, Y Minami; S Kawamoto, K Yamamoto, M Ito, R Tominaga, H Gomyo, I Mizuno, T Nomura, K Kitagawa, T Sugimoto, T Murayama, H Matsuoka, and H Minami
Int J Hematol, 104 (6): 682-691, 2016

41) Coexpression of *NUP98/TOPI* and *TOPI/NUP98* in *de novo* acute myeloid leukemia with t(11;20)(p15;q12) and t(2;5)(q33;q31)
K Yamamoto, Y Minami, K Yakushijin, Y Mizutani, Y Inui, S Kawamoto, K Matsui, Y Nakamachi, S Kawano, H Matsuoka, and H Minami
Cytogenet Genome Res, 150: 287-292, 2016

42) NANOG expression as a responsive biomarker during treatment with Hedgehog inhibitor in acute myeloid leukemia
S Kakiuchi, Y Minami (Corresponding Author), Y Miyata, Y Mizutani, H Goto, S Kawamoto, K Yakushijin, K Kurata, H Matsuoka, and H Minami
Int J Mol Sci, 18 (3): 486, 2017

43) Phase I study of single-agent glasdegib (PF-04449913), an oral hedgehog pathway inhibitor, in Japanese patients with select hematologic malignancies in acute myeloid leukemia
Y Minami (Corresponding Author), H Minami, T Miyamoto, G Yoshimoto, Y Kobayashi, Y Onishi, M Ikuta, G Chan, A Woolfson, C Ono, MN Shaik, Y Fujii, X Zheng, and T Naoe
Cancer Sci, 108 (8): 1628-1633, 2017

44) Deeper molecular response is an independent predictive factor for successful treatment-free remission after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia: JALSG-STIM213 Study
N Takahashi, T Tauchi, K Kitamura, K Miyamura, Y Saburi, Y Hatta, Y Miyata, F Kimura, K Usuki, I Matsumura, Y Minami, N Usui, T Fukuda, S Takada, M Ishikawa, K Fujimaki, T Murayama, O Sasaki, K Ohishi, T Miyake, K Imai, H Suzushima, H Mitsui, M Mori, T Kiguchi, Y Atsuta, S Ohtake, K Ohnishi, Y Kobayashi, H Kiyoi, Y Miyazaki, T Naoe and the Japan Adult Leukemia Study Group
Int J Hematol, 107: 185-193, 2018

45) Final 3 year results of the DADI Trial: immune profile correlates with treatment-free remission after discontinuation of second- or subsequent-line dasatinib for chronic myeloid leukemia
M Okada, J Imagawa, H Tanaka, H Nakamae, M Hino, K Murai, Y Ishida, T Kumagai, S Sato, K Ohashi, H Sakamaki, H Wakita, N Uoshima, Y Nakagawa, Y Minami, M Ogasawara, T Takeoka, H Akasaka, T Utsumi, N Uike, T Sato, S Ando, K Usuki, S Mizuta, T Nomura, S Hashino, M Shikami, H Fukutani, Y Ohe, H Kosugi, H Shibayama, T Fukushima, Y Maeda, H Yamazaki, K Tsubaki, T Kukita, Y Adachi, T Nataduka, H Sakoda, H Yokoyama, Y Shirasugi, Y Onishi, T Okamoto, M Nohgawa, S Yoshihara, S Morita, J Sakamoto, and SKimura
Clinical Lymphoma, Myeloma and Leukemia, 18 (5): 353-360, 2018

46) Molecular target therapies for overcoming resistance and disease persistence in chronic

myeloid leukemia

A Inoue, CI Kobayashi, H Shinohara, K Miyamoto, N Yamauchi, J Yuda, Y Akao, and Y Minami (Corresponding Author)

Int J Hematol, 108 (4): 365-670, 2018

47) Guest editorial: Chronic myeloid leukemia

Y Minami (Corresponding Author)

Int J Hematol, 108 (4): 353-354, 2018

48) Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein

H Shinohara, Y Minami, T Naoe, and Y Akao

Haematologica, e-published

49) Potent anti-proliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL kinase domain mutation

H Shinohara, N Sugito, Y Kuranaga, K Heishima, Y Minami, T Naoe, and Y Akao

Cancer Sci, 110 (2): 751-760, 2019

50) Targeting Hedgehog (Hh) pathway for the acute myeloid leukemia treatment

T Terao and Y Minami (Corresponding Author)

Cells, in press, 2019